CD47 and cancer: Flow cytometry showed that 9.75 and 4.54% of the macrophages engulfed cancer cells in the anti-CD47 mAb-alone and bevacizumab treatment, respectively, for SGC-7901 cells, and for BGC-823 cells, the percentages were 28.63 and 22.90%, respectively, which was much higher than that of the bevacizumab group or the IgG1 isotype group.